- "Building Momentum for Patients with
Myelofibrosis" scheduled for 6:00 p.m.
GMT on November 20, 2019 -
VANCOUVER, Nov. 14, 2019 /PRNewswire/ - Sierra Oncology,
Inc. (Nasdaq: SRRA), a late-stage drug development company focused
on the development and commercialization of momelotinib, a JAK1,
JAK2 & ACVR1 inhibitor with a potentially differentiated
therapeutic profile for the treatment of myelofibrosis, today
announced that Dr. Nick Glover,
President and Chief Executive Officer, will present an overview of
the company entitled "Building Momentum for Patients with
Myelofibrosis" at the Jefferies 2019 London Healthcare Conference
in London, United Kingdom.
The presentation is scheduled for 6:00 p.m. GMT on Wednesday, November 20, 2019. A live audio
webcast and archive of the presentation will be accessible through
www.sierraoncology.com.
About Sierra Oncology
Sierra Oncology is a late stage
drug development company focused on advancing targeted therapeutics
for the treatment of patients with significant unmet medical needs
in hematology and oncology.
Momelotinib, Sierra's lead drug candidate, is a potent,
selective and orally-bioavailable JAK1, JAK2 & ACVR1 inhibitor
with a differentiated therapeutic profile in myelofibrosis
encompassing robust constitutional symptom improvements, a range of
meaningful anemia benefits, including eliminating or reducing the
need for frequent blood transfusions, and comparable spleen control
to ruxolitinib. More than 1,200 subjects have received momelotinib
since clinical studies began in 2009, including more than 800
patients treated for myelofibrosis. Sierra plans to launch the
MOMENTUM Phase 3 clinical trial in the fourth quarter of 2019 to
support potential registration of momelotinib on a global basis.
Momelotinib is wholly owned by Sierra Oncology and is covered by
patents anticipated to provide potential exclusivity to 2040 in
the United States and Europe (including Patent Term Extension or
Supplementary Protection Certificate).
Sierra is also developing a portfolio of DNA Damage Response
(DDR) assets, consisting of SRA737 and SRA141, and is conducting a
campaign intended to seek non-dilutive strategic options to support
their further advancement. SRA737 is a potent, highly selective,
orally bioavailable small molecule inhibitor of Checkpoint kinase 1
(Chk1), a key regulator of cell cycle progression and the DDR, and
has demonstrated preliminary clinical efficacy. SRA141 is a potent,
selective, orally bioavailable small molecule inhibitor of Cell
division cycle 7 kinase (Cdc7) with a potential novel mechanism of
cytotoxicity, and has successfully completed the IND process with
the FDA enabling the commencement of clinical trials. Sierra
retains the global commercialization rights to SRA737 and
SRA141.
For more information, please visit www.sierraoncology.com.
Cautionary Note on Forward-Looking Statements
This
press release contains forward-looking statements within the
meaning of the "safe harbor" provisions of the Private Securities
Litigation Reform Act of 1995, including, but not limited to,
statements regarding Sierra Oncology's expectations from current
data, anticipated clinical development activities, timing of the
initiation of MOMENTUM, and potential benefits of Sierra Oncology's
lead product candidate and other product candidates. All statements
other than statements of historical fact are statements that could
be deemed forward-looking statements. These statements are based on
management's current expectations and beliefs and are subject to a
number of risks, uncertainties and assumptions that could cause
actual results to differ materially from those described in the
forward-looking statements. Such forward-looking statements are
subject to risks and uncertainties, including, among others, the
risk that Sierra Oncology may be unable to successfully develop and
commercialize product candidates, product candidates may not
demonstrate safety and efficacy or otherwise produce positive
results, Sierra Oncology may experience delays in the preclinical
and anticipated clinical development of its product candidates,
Sierra Oncology may be unable to acquire additional assets to build
a pipeline of additional product candidates, Sierra Oncology's
third-party manufacturers may cause its supply of materials to
become limited or interrupted or fail to be of satisfactory
quantity or quality, Sierra Oncology's cash resources may be
insufficient to fund its current operating plans and it may be
unable to raise additional capital when needed, Sierra Oncology may
be unable to obtain and enforce intellectual property protection
for its technologies and product candidates and the other factors
described under the heading "Risk Factors" set forth in Sierra
Oncology's filings with the Securities and Exchange Commission from
time to time. Sierra Oncology undertakes no obligation to update
the forward-looking statements contained herein or to reflect
events or circumstances occurring after the date hereof, other than
as may be required by applicable law.
View original
content:http://www.prnewswire.com/news-releases/sierra-oncology-to-present-at-the-jefferies-2019-london-healthcare-conference-300958733.html
SOURCE Sierra Oncology